Your session is about to expire
← Back to Search
Behavioural Intervention
Repetitive Transcranial Magnetic Stimulation for Mild Cognitive Impairment
N/A
Recruiting
Research Sponsored by University of Arizona
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Age 50-80 years
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months after the intervention phase complete
Summary
This trial will use a personalized, non-invasive brain stimulation protocol to prevent cognitive decline in patients with mild cognitive impairment (MCI) and cognitively normal individuals at high risk of developing Alzheimer's disease (AD).
Who is the study for?
This trial is for English-speaking individuals aged 50-80 with mild cognitive impairment (MCI), who can attend daily sessions for 4 weeks, and haven't been in another study recently. They should have certain scores on cognitive tests like the MMSE or MoCA, be right-handed, and not have dementia.
What is being tested?
The study aims to prevent cognitive decline using repetitive transcranial magnetic stimulation (rTMS). It involves personalized brain stimulation guided by MRI imaging to enhance memory and delay Alzheimer's disease progression in those at high risk.
What are the potential side effects?
While rTMS is generally considered safe, potential side effects may include discomfort at the stimulation site, headache, lightheadedness, or rare seizures.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am between 50 and 80 years old.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3 months after the intervention phase complete
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months after the intervention phase complete
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Specimen sample
Other study objectives
Brain
Correction rate in memory association recall
NACC Neuropsychological batteries
Trial Design
3Treatment groups
Experimental Treatment
Placebo Group
Group I: Inhibitory TBSExperimental Treatment1 Intervention
Inhibitory TBS
Group II: Excitatory TBSExperimental Treatment1 Intervention
Excitatory TBS
Group III: Sham TBSPlacebo Group1 Intervention
Sham TBS
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
TBS
2022
N/A
~90
Find a Location
Who is running the clinical trial?
University of ArizonaLead Sponsor
539 Previous Clinical Trials
161,616 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,803 Previous Clinical Trials
28,193,951 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You must be able to speak English.You have not participated in another research study that involves receiving treatment within the past 6 months.You have difficulty with thinking and memory as shown by certain tests, such as the MMSE or MoCA, with scores between 24-27 or 18-26, respectively. Or, you have a Clinical Dementia Rating Scale score of 0.5.I can attend a daily session every weekday for 4 weeks.You have noticed problems with your memory or thinking, but you can still do things on your own without help. You do not have dementia.You have mild problems with your memory and thinking abilities.I am between 50 and 80 years old.You use your right hand dominantly.
Research Study Groups:
This trial has the following groups:- Group 1: Sham TBS
- Group 2: Excitatory TBS
- Group 3: Inhibitory TBS
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.